Development and validation of a prognostic nomogram for predicting early recurrence after curative resection of stage II/III gastric cancer

Table 3 The early recurrence rate of patients with stage III gastric cancer

Variable	Adjuvant chemotherapy ≥ 6 cycles	Adjuvant chemotherapy < 6 cycles	P
Tumor location
Lower third	27/206 (13.1%)	114/434 (26.3%)	< 0.001
Upper, middle third, or mixed	28/132 (21.2%)	114/280 (40.7%)	< 0.001
Positive lymph node ratio
< 0.335	15/172 (8.7%)	74/371 (19.9%)	0.001
≥ 0.335	40/166 (24.1%)	154/343 (44.9%)	< 0.001
Lymphocyte count
≥ 1.5 × 10⁹/L	31/214 (14.5%)	124/439 (28.2%)	< 0.001
< 1.5 × 10⁹/L	24/124 (19.4%)	104/275 (37.8%)	< 0.001
Postoperative infection complications
No	51/318 (16.0%)	202/661 (30.6%)	< 0.001
Yes	4/20 (20.0%)	26/53 (49.1%)	0.024

ISSN: 1477-7819